Securities Law Firm Files Lawsuit Against MoonLake Immunotherapeutics

Strategic Insights -

A leading securities law firm has filed a lawsuit against MoonLake Immunotherapeutics, a clinical-stage biotechnology company, and certain senior executives for potential violations of federal securities laws. The lawsuit, captioned Bridgewood v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08500, is pending in the U.S. District Court for the Southern District of New York. Investors in MoonLake common stock are encouraged to obtain additional information by visiting the firm's website.

The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in MoonLake common stock. The lawsuit claims that MoonLake made false and misleading statements to investors about the clinical data and Nanobody structure of its investigational therapeutic, sonelokimab. The company's stock price declined by nearly 90% after MoonLake reported disappointing results from its Phase 3 VELA trials.

Key Takeaways:

  • MoonLake Immunotherapeutics and certain senior executives are being sued for potential violations of federal securities laws.
  • The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Bridgewood v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08500.
  • Investors in MoonLake common stock are encouraged to obtain additional information by visiting the firm's website.
  • The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in MoonLake common stock.
  • MoonLake made false and misleading statements to investors about the clinical data and Nanobody structure of its investigational therapeutic, sonelokimab.
  • The company's stock price declined by nearly 90% after MoonLake reported disappointing results from its Phase 3 VELA trials.
  • The Securities Law Firm is filing the lawsuit on behalf of investors who purchased MoonLake common stock during the period from January 19, 2023, to September 25, 2025.
  • The firm's attorneys have significant experience in securities class actions and shareholder litigation, including recovering over $900 million in value from Tesla, Inc.'s Board of Directors and $420 million from Teva Pharmaceutical Ind. Ltd.

Statistics:

  • 90% decline in MoonLake stock price after reporting disappointing results from Phase 3 VELA trials.
  • $55.75 per share decrease in MoonLake stock price from September 26, 2025, to September 29, 2025.
  • Over 90% of investors may be affected by the lawsuit, according to the Securities Law Firm.
  • The lawsuit is pending in the U.S. District Court for the Southern District of New York, No. 1:25-cv-08500.

Sources:

  • GlobeNewswire, "Securities Law Firm Files Lawsuit Against MoonLake Immunotherapeutics and Senior Executives for Securities Fraud" (October 24, 2025)
  • MoonLake Immunotherapeutics, "MoonLake Reports Week 16 Results from VELA Phase 3 Trials" (September 28, 2025)
  • Bleichmar Fonti & Auld LLP, "BFA Announces Securities Class Action Lawsuit Against MoonLake Immunotherapeutics and Senior Executives" (October 24, 2025)